These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 16026226

  • 1. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
    McGough JJ, Pataki CS, Suddath R.
    Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
    [Abstract] [Full Text] [Related]

  • 2. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group.
    Biol Psychiatry; 2007 Jun 15; 61(12):1380-7. PubMed ID: 17137560
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D.
    Expert Opin Pharmacother; 2009 Nov 15; 10(16):2679-85. PubMed ID: 19874250
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
    Moen MD, Keam SJ.
    CNS Drugs; 2009 Dec 15; 23(12):1057-83. PubMed ID: 19958043
    [Abstract] [Full Text] [Related]

  • 9. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Dec 15; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 10. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 15; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 11. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M, Mao AR, Doyle RL.
    Postgrad Med; 2008 Sep 15; 120(3):69-88. PubMed ID: 18824827
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
    Childress AC, Spencer T, Lopez F, Gerstner O, Thulasiraman A, Muniz R, Post A.
    J Child Adolesc Psychopharmacol; 2009 Aug 15; 19(4):351-61. PubMed ID: 19702487
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 15; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 14. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE, Kratochvil CJ.
    Drugs; 2010 Feb 15; 70(1):15-40. PubMed ID: 20030423
    [Abstract] [Full Text] [Related]

  • 15. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec 15; 13(74):203-6. PubMed ID: 15612099
    [Abstract] [Full Text] [Related]

  • 16. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun 15; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 17. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
    Drugs R D; 2002 Jun 15; 3(4):279-82. PubMed ID: 12455205
    [Abstract] [Full Text] [Related]

  • 18. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M.
    Expert Rev Neurother; 2009 Aug 15; 9(8):1121-31. PubMed ID: 19673602
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 15; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.